Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06764485 · ClinicalTrials.gov registry record · Phase 3

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

A Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Celgene.

Recruiting
Registry status
Phase 3
Development phase
960
Enrollment target
20
Study locations

NCT06764485: Recruiting Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Celgene.

NCT06764485 is a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Celgene. The registered enrollment target is 960 participants, above the 184-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (422% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06764485, a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Celgene.

RECRUITING
Registry status
Phase 3
Development phase
960 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG Docetaxel
  • DRUG Enzalutamide
  • DRUG Abiraterone
  • DRUG BMS-986365
  • DRUG Predinsone/Prednisolone

Study Locations (20)

California

  • Los Angeles Cancer Network (LACN) - Anaheim
  • Moores Cancer Center - La Jolla
  • Cancer and Blood Specialty Clinic - Los Alamitos
  • Local Institution - 0364 - Los Angeles
  • Pacific Hematology Oncology Associates - San Francisco
  • San Francisco VA Health Care System - San Francisco

Colorado

  • Rocky Mountain Regional VA Medical Center - Aurora
  • Rocky Mountain Cancer Centers, LLP - Denver
  • Colorado Clinical Research - Lakewood

Maryland

  • Chesapeake Urology - Baltimore
  • Johns Hopkins Hospital - Baltimore
  • James M Stockman Cancer Institute - Frederick

Kansas

  • The University of Kansas Cancer Center - Westwood - Westwood
  • Wichita Urology Group - Wichita

Alabama

  • Central Alabama Research - Birmingham

Arizona

  • Banner MD Anderson Cancer Center - Gilbert

District of Columbia

  • Sibley Memorial Hospital - Washington D.C.

Florida

  • Lakeland Regional Cancer Center - Lakeland

Trial Details

FieldValue
Enrollment Target 960 participants
Start Date 2025-03-13
Est. Completion 2029-01-19
Phase Phase 3
Celgene

308 total trials

What NCT06764485 shows while recruiting

NCT06764485 is an interventional study that assigns participants to a tested intervention. The registered 960 participants enrollment target is mid-sized for trials with a published cap, above the 184-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (422% higher).

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.

NCT06764485 names 20 study sites across 10 states, led by California, Colorado, Maryland.

Frequently Asked Questions

What is clinical trial NCT06764485 about?

NCT06764485 is a clinical study titled "A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer". The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.

What is the current status of trial NCT06764485?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 960 participants. The study started on 2025-03-13. Estimated completion is 2029-01-19.

What conditions does trial NCT06764485 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT06764485?

The interventions under investigation include: Docetaxel (DRUG), Enzalutamide (DRUG), Abiraterone (DRUG), BMS-986365 (DRUG), Predinsone/Prednisolone (DRUG).

Who is sponsoring clinical trial NCT06764485?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06764485 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06764485's enrollment target sits among peer trials

960 3rd of 69 higher than 67 of 69 other Metastatic Castration-Resistant Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04726241 · 960 participants · Phase 1

    The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • NCT05142384 · 960 participants · NA

    ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start

  • NCT05178498 · 960 participants

    Impact of Dietary Inflammatory Potential on Breast Cancer Risk

  • NCT05946629 · 960 participants · NA

    SELUTION 4 De Novo Small Vessel IDE Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06764485

Source: ClinicalTrials.gov NCT06764485, the US trial registry maintained by the National Library of Medicine. NCT06764485 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.